Cynthia Huisman

Summary

Country: The Netherlands

Publications

  1. doi request reprint Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years
    Cynthia Huisman
    Department of Hematology, University Medical Center, Utrecht, The Netherlands
    Biol Blood Marrow Transplant 14:181-6. 2008
  2. doi request reprint Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
    Evelien Kneppers
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 118:2413-9. 2011
  3. doi request reprint NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation
    Hanneke M van der Straaten
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Biol Blood Marrow Transplant 17:1231-6. 2011

Collaborators

Detail Information

Publications3

  1. doi request reprint Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years
    Cynthia Huisman
    Department of Hematology, University Medical Center, Utrecht, The Netherlands
    Biol Blood Marrow Transplant 14:181-6. 2008
    ..In conclusion, fludarabine plus low-dose TBI-based RIC HSCT is effective in AML patients over the age of 40 years without active disease at the time of transplant and is associated with low TRM...
  2. doi request reprint Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
    Evelien Kneppers
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 118:2413-9. 2011
    ..This trial was registered at www.trialregister.nl as #NTR1645...
  3. doi request reprint NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation
    Hanneke M van der Straaten
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Biol Blood Marrow Transplant 17:1231-6. 2011
    ..Therefore, screening for NOD2/CARD15 polymorphisms in patients or donors does not have additional value in patients undergoing nonmyeloablative SCT...